PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

[1]  Shih-Hsun Chen,et al.  Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[2]  I. Horváth,et al.  Silencing of Poly(ADP-Ribose) Polymerase-2 Induces Mitochondrial Reactive Species Production and Mitochondrial Fragmentation , 2021, Cells.

[3]  W. Kraus,et al.  Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance , 2021, Experimental & molecular medicine.

[4]  Sarah A. Boswell,et al.  Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer , 2020, Nature Cancer.

[5]  R. Deberardinis,et al.  1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer , 2020, Science Advances.

[6]  Claire O'Donovan,et al.  MetaboLights: a resource evolving in response to the needs of its scientific community , 2019, Nucleic Acids Res..

[7]  T. Aas,et al.  Neoadjuvant olaparib monotherapy in primary triple negative breast cancer , 2019, Annals of Oncology.

[8]  Rochelle L. Garcia,et al.  Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. , 2019, Gynecologic oncology.

[9]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[10]  B. Becher,et al.  ARTD1 in Myeloid Cells Controls the IL-12/18–IFN-γ Axis in a Model of Sterile Sepsis, Chronic Bacterial Infection, and Cancer , 2019, The Journal of Immunology.

[11]  D. Cescon,et al.  AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer , 2019, Proceedings of the National Academy of Sciences.

[12]  J. Rabinowitz,et al.  Nicotinamide adenine dinucleotide is transported into mammalian mitochondria , 2018, eLife.

[13]  Ellen L. Robb,et al.  Control of mitochondrial superoxide production by reverse electron transport at complex I , 2018, The Journal of Biological Chemistry.

[14]  E. Pålsson-McDermott,et al.  Metabolic Modulation in Macrophage Effector Function , 2018, Front. Immunol..

[15]  L. Groop,et al.  N1-methylnicotinamide is a signalling molecule produced in skeletal muscle coordinating energy metabolism , 2018, Scientific Reports.

[16]  A. Triantafyllopoulou,et al.  DNA damage signaling and polyploid macrophages in chronic inflammation. , 2018, Current opinion in immunology.

[17]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[18]  Z. Yao,et al.  Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. , 2017, Journal of thoracic disease.

[19]  F. Kittrell,et al.  Macrophages promote the progression of premalignant mammary lesions to invasive cancer. , 2017, Oncotarget.

[20]  R. Xavier,et al.  Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages , 2016, Cell.

[21]  L. Cantley,et al.  Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion , 2016, Proceedings of the National Academy of Sciences.

[22]  K. Gelmon,et al.  Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  G. Mbalaviele,et al.  ARTD1 regulates osteoclastogenesis and bone homeostasis by dampening NF-κB-dependent transcription of IL-1β , 2016, Scientific Reports.

[24]  Ayala Hubert,et al.  Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.

[25]  T. Uzu,et al.  1-Methylnicotinamide ameliorates lipotoxicity-induced oxidative stress and cell death in kidney proximal tubular cells. , 2015, Free radical biology & medicine.

[26]  S. Fernández-Arroyo,et al.  Reshaping of Human Macrophage Polarization through Modulation of Glucose Catabolic Pathways , 2015, The Journal of Immunology.

[27]  M. Hottiger,et al.  ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation , 2015, Molecular and Cellular Biology.

[28]  L. Liaudet,et al.  Poly(ADP-ribose) polymerases as modulators of mitochondrial activity , 2015, Trends in Endocrinology & Metabolism.

[29]  Robert W Sobol,et al.  ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion. , 2014, Cell reports.

[30]  V. Malmström,et al.  An optimized Protocol for Human M2 Macrophages using M-CSF and IL-4/IL-10/TGF-β Yields a Dominant Immunosuppressive Phenotype , 2014, Scandinavian journal of immunology.

[31]  S. Schuster,et al.  Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. , 2013, Nature chemical biology.

[32]  Jens-Peter Volkmer,et al.  Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.

[33]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[34]  D. Dewitt,et al.  Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. , 2012, Biochemical pharmacology.

[35]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[36]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[37]  J. Peterse,et al.  Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.

[38]  Jos Jonkers,et al.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.

[39]  W. Sivitz,et al.  Reactive Oxygen and Targeted Antioxidant Administration in Endothelial Cell Mitochondria* , 2006, Journal of Biological Chemistry.

[40]  R. Schwendener,et al.  Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.

[41]  G. Wang,et al.  Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8 , 2006, Nature Methods.

[42]  James M. Anderson,et al.  Multinucleated giant cell formation exhibits features of phagocytosis with participation of the endoplasmic reticulum. , 2005, Experimental and molecular pathology.

[43]  V. Schreiber,et al.  PARP-1 and PARP-2 interact with nucleophosmin/B23 and accumulate in transcriptionally active nucleoli , 2005, Journal of Cell Science.

[44]  D. Hsu,et al.  Critical role of galectin-3 in phagocytosis by macrophages. , 2003, The Journal of clinical investigation.

[45]  B. Edgar,et al.  Endoreplication Cell Cycles More for Less , 2001, Cell.

[46]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[47]  O. Kollet,et al.  NOD/LtSz-Rag1null Mice: An Immunodeficient and Radioresistant Model for Engraftment of Human Hematolymphoid Cells, HIV Infection, and Adoptive Transfer of NOD Mouse Diabetogenic T Cells1 , 2000, The Journal of Immunology.

[48]  C. Bogdan,et al.  The role of nitric oxide in innate immunity , 2000, Immunological reviews.

[49]  J. Curtsinger,et al.  CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. , 1998, Journal of immunology.

[50]  K. Shiwaku,et al.  Radical formation site of cerebral complex I and Parkinson's disease , 1995, Journal of neuroscience research.

[51]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition. , 2001, The Biochemical journal.

[52]  O. Kollet,et al.  NOD/LtSz-Rag1 Mice: An Immunodeficient and Radioresistant Model for Engraftment of Human Hematolymphoid Cells, HIV Infection, and Adoptive Transfer of NOD Mouse Diabetogenic T Cells , 2000 .